











































Combined Mesenchymal Stromal Cell Therapy and ECMO in
ARDS
Citation for published version:
Combining Extracorporeal Life Support and Cell Therapy in Critical Illness (CELTIC) investigators. & Millar,
J 2020, 'Combined Mesenchymal Stromal Cell Therapy and ECMO in ARDS: A Controlled Experimental
Study in Sheep', American Journal of Respiratory and Critical Care Medicine.
https://doi.org/10.1164/rccm.201911-2143OC
Digital Object Identifier (DOI):
10.1164/rccm.201911-2143OC
Link:




American Journal of Respiratory and Critical Care Medicine
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 23. Jul. 2021
Combined Mesenchymal Stromal Cell Therapy and ECMO in ARDS: A Controlled 
Experimental Study in Sheep
Jonathan E Millar1,2,3, Nicole Bartnikowski1,4, Margaret R Passmore1,2, Nchafatso G Obonyo1,5, 
Maximillian V Malfertheiner1,6, Viktor von Bahr1,7, Meredith A Redd8, Louise See Hoe1,2, 
Katrina K Ki1,2, Sanne Pedersen1,4, Andrew J Boyle3, J Kenneth Baillie9, Kiran Shekar1,2, 
Nathan Palpant8, Jacky Y Suen1,2, Michael A Matthay10, Daniel F McAuley3, John F Fraser1,2 
on behalf of the Combining Extracorporeal Life Support and Cell Therapy in Critical Illness 
(CELTIC) investigators.
1 Critical Care Research Group, The Prince Charles Hospital, Brisbane, Australia.
2 Faculty of Medicine, University of Queensland, Australia.
3 Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, 
United Kingdom.
4 Institute of Health and Biomedical Innovation, Queensland University of Technology, 
Australia.
5 Wellcome Trust Centre for Global Health Research, Imperial College London, United 
Kingdom.
6 Department of Internal Medicine II, Cardiology and Pneumology, University Medical 
Center Regensburg, Germany.
7 Department of Physiology and Pharmacology, Section for Anesthesiology and Intensive 
Care Medicine, Karolinska Institutet, Stockholm, Sweden.
8 Institute for Molecular Bioscience, University of Queensland, Australia.
9 Roslin Institute, University of Edinburgh, United Kingdom
Page 1 of 66
 AJRCCM Articles in Press. Published April 15, 2020 as 10.1164/rccm.201911-2143OC 
 Copyright © 2020 by the American Thoracic Society 
10 Departments of Medicine and Anesthesia, Cardiovascular Research Institute, University of 
California, San Francisco, United States of America.
Corresponding author
Dr Jonathan E. Millar
Critical Care Research Group
The Prince Charles Hospital,
Chermside, Brisbane, Queensland, Australia, 4032
Telephone: +44 (0) 7545579065
Email: j.millar@doctors.org.uk
Authors contributions
J.E.M. – study conception, model development, study design and conduct, animal surgery, 
data collection and analyses, manuscript preparation.
N.B., J.Y.S. – model development, study design and conduct, data collection and analyses, 
manuscript review.
N.G.O., M.V.M., V.vB. – model development, study design and conduct, animal surgery, 
manuscript review.
M.A.R., M.R.P., K.K.K. – sample analyses, data analyses, manuscript review.
S.P. - model development, study design and conduct, animal surgery, manuscript review.
J.K.B. – data analysis, manuscript review.
N.P., A.J.B, M.A.M. - study design, data interpretation, manuscript review.
D.F.M., J.F.F. - study conception, model development, study design, data interpretation, 
manuscript review.
Page 2 of 66
 AJRCCM Articles in Press. Published April 15, 2020 as 10.1164/rccm.201911-2143OC 
 Copyright © 2020 by the American Thoracic Society 
Funding sources
We gratefully acknowledge funding from the Intensive Care Society (UK), The Prince Charles 
Hospital Foundation, the Queensland Government, and the National Health and Medical 
Research Council (Australia). We also acknowledge the endorsement of this study by the 
International ECMO Network (ECMONet). Mesenchymal stromal cells were donated in-kind, 
under a material transfer agreement, by Cynata Therapeutics Ltd., Melbourne, Australia. 
Cynata Therapeutics Ltd. was not involved in the conception, design, or analysis of the study. 
Prof. Matthay is supported by NHLBI HL123004, HL140026, HL126456.  
Running title
Combined MSC therapy and ECMO in experimental ARDS
Subject category classification
4.1 ALI/ARDS: Biological Mechanisms
Manuscript word count
3,086 words
At a glance commentary
Scientific knowledge on the subject:
Mesenchymal stromal cell (MSC) therapy is a promising novel intervention for ARDS. Trials 
to date have failed to explore the safety of cell therapy during ECMO. Pre-clinical 
investigations have found that MSC therapy during ECMO attenuate the efficacy of ECMO. 
What this study adds to the field:
This study, employing a 24-hour, large animal model of ARDS and ECMO, examined the 
safety and efficacy of MSC therapy. We found that endobronchially administered MSCs adhere 
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to, and impair, membrane oxygenators in-vivo. MSCs did not improve oxygenation or other 
ventilatory parameters but did reduce the severity of histological evidence of lung injury. Our 
data also suggest that MSCs may reduce circulatory shock associated with ARDS. There were 
no adverse effects of MSC administration on renal or liver function.   
Online data supplement
This article has an online data supplement, which is accessible from this issue’s table of 
content online at www.atsjournals.org. 
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Abstract
Rationale
Mesenchymal stromal cell therapy is a promising intervention for ARDS, although 
trials to date have not investigated its use alongside ECMO. Recent pre-clinical studies have 
suggested that combining these interventions may attenuate the efficacy of ECMO.
Objectives
To determine the safety and efficacy of mesenchymal stromal cell therapy in a model 
of ARDS and ECMO. 
Methods
ARDS was induced in 14 sheep, after which they were established on veno-venous 
ECMO. Subsequently, they received either, endobronchial iPSC-derived human MSCs 
(hMSCs, n=7) or cell-free carrier vehicle (Vehicle control, n=7).  During ECMO, a low tidal 
volume ventilation strategy was employed in addition to protocolized hemodynamic support. 
Animals were monitored and supported for 24 hours. Lung tissue, bronchoalveolar fluid, and 
plasma were analysed, in addition to continuous respiratory and hemodynamic monitoring.
Measurements and main results
The administration of hMSCs did not improve oxygenation (PaO2/FiO2 mean 
difference -146 mmHg, p = 0.076) or pulmonary function. However, histological evidence of 
lung injury (Lung Injury Score mean difference -0.07, p = 0.04) and BAL IL-8 were reduced. 
In addition, hMSC treated animals had a significantly lower cumulative requirement for 
vasopressor. Despite endobronchial administration, animals treated with hMSCs had a 
significant elevation in trans-membrane oxygenator pressure gradients. This was accompanied 
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by more pulmonary artery thromboses and adherent hMSCs found on explanted oxygenator 
fibers.   
Conclusions
Endobronchial hMSC therapy in an ovine model of ARDS and ECMO can impair 
membrane oxygenator function and does not improve oxygenation. These data do not 
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Introduction
The quest for an effective pharmacological treatment for the Acute Respiratory Distress 
Syndrome (ARDS) has been unsuccessful. Recently, mesenchymal stromal cells (MSCs) have 
attracted attention as a candidate therapy for ARDS (1).
MSCs are multipotent adult stem cells found in tissues of mesodermal origin such as 
bone marrow (2). Therapeutic interest in these cells has arisen because of their pleiotropic 
immunomodulatory abilities. During acute inflammation, MSCs appear to be 
immunosuppressive, influencing both innate and adaptive immune responses (3). In ARDS, 
their beneficial effects are believed to be mediated in a variety of ways, including; secretion of 
anti-inflammatory paracrine factors (4), restoration of epithelial and endothelial integrity (5), 
enhancement of alveolar fluid clearance (6), direct antimicrobial activity (7), and by 
mitochondrial transfer (8). In pre-clinical models of acute lung injury, MSCs have been shown 
to reduce mortality (9). A phase 2 study has been conducted in patients with ARDS with no 
reported infusion-related adverse events (10).  
To date, trials of MSCs in ARDS have excluded patients supported with extracorporeal 
membrane oxygenation (ECMO). The use of ECMO in acute severe respiratory failure has 
increased substantially in the last decade and is now an established tool for supporting those 
with refractory illness (11). The use of MSCs during ECMO, while potentially attractive, raises 
some unique considerations. Firstly, MSCs are large cells, with an average diameter between 
10-30 µm (12), which when administered therapeutically may pose a risk to the patency of a 
membrane oxygenator. Secondly, a defining characteristic of MSCs is avid plastic adherence 
(13); this too may threaten membrane oxygenators, which are constructed largely from plastics. 
Recent ex-vivo and small animal experimentation has confirmed these concerns (14, 15). 
Page 7 of 66
 AJRCCM Articles in Press. Published April 15, 2020 as 10.1164/rccm.201911-2143OC 
 Copyright © 2020 by the American Thoracic Society 
Conversely, immunomodulation by MSCs may provide additional benefits for ECMO patients, 
where the institution of extracorporeal support results in an additional inflammatory insult (16).
Given the paucity of evidence to support the safe use of MSC therapy during ECMO, 
we conducted a controlled trial of clinical-grade induced pluripotent stem cell (iPSC) derived 
human MSCs (hMSCs) in an ovine model of ARDS, supported with veno-venous ECMO (VV-
ECMO). The primary objective was to assess the safety of MSC therapy and to investigate its 
effect on physiologic and biologic markers of pulmonary and systemic injury.          
Methods
Study design
Ethical approvals were obtained from University Animal Ethics Committees 
(QUT1600001108, UQPCH/483/17) and authorization for in-vivo use of hMSCs was granted 
by the Australian Department of Agriculture (2017/075). The study was conducted in 
accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific 
Purposes (17) and is reported in compliance with ARRIVE guidelines (18). Detailed methods 
and a comprehensive description of the experiments and analyses are provided in an online 
supplement. A schematic of the study protocol is provided in Figure 1.  
Animal model
Fourteen healthy Border Leicester Cross ewes aged between 1-3 years and weighing 
between 46-55 kg (mean, 52.6 ± 3 kg), were randomly assigned to one of two groups; 
endobronchial iPSC-derived hMSC treatment (n=7) or endobronchial carrier vehicle only 
(n=7). 
In brief, animals were anesthetized with a combination of ketamine, midazolam, and 
fentanyl. Continuous neuromuscular blockade was maintained by infusion of vecuronium. In a 
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supine position, animals were tracheostomized and ventilated using a low tidal volume strategy 
(6 mL/kg actual body weight (ABW)). After instrumentation, acute lung injury was induced 
by combining an intravenous infusion of oleic acid (OA; 0.06 mL/kg; O1008, Sigma-Aldrich, 
Castle Hill, NSW, Australia) with endobronchial E. coli lipopolysaccharide (LPS; 100 µg; 
O55:B5, Sigma-Aldrich, Castle Hill, NSW, Australia). Once a PaO2/FiO2 ratio < 100 mmHg 
(PEEP ≥ 10 cmH2O) was obtained (T0), animals were established on VV-ECMO via a right-
sided jugular-jugular configuration (T1) and positioned in sternal recumbency. VV-ECMO was 
combined with a lower tidal volume strategy (4 mL/kg ABW) for 22 hours, at which time (T23) 
ECMO was stopped and a standardized recruitment manoeuvre was performed. Animals were 
returned to pre-ECMO ventilatory settings for one hour before being euthanized (T24).      
iPSC-derived hMSCs
After one hour of VV-ECMO (T2), animals received a fixed dose of 3 x 108 iPSC-
derived hMSCs suspended in a carrier vehicle (hMSC) or carrier vehicle alone (Vehicle 
control). Cells were provided by Cynata Therapeutics Ltd. (CYP-001; Cynata Therapeutics 
Ltd., Melbourne, VIC, Australia). These cells were ≥ 99% positive for CD-73, CD-90, and CD-
105, but negative for CD-31 and CD-45. The total volume of vehicle was 60 mL (57.5% 
Plasmalyte-A, 40% Flexbumin 25%, 2.5% Dimethyl sulfoxide). Cells were ≥ 97% viable prior 
to administration. The distribution of delivery is described in Figure E1. 
Statistical analysis 
An a priori sample size calculation, based on the primary outcome of PaO2/FiO2 ratio 
at 24 hours,  is detailed in the online supplement. Data are expressed as mean (± SD) or median 
(IQR) if non-normally distributed. Analysis was undertaken in Graphpad Prism (v 8.1.2., 
GraphPad Software, San Diego, USA). Longitudinal data were analyzed by fitting a mixed 
model. This model uses a compound symmetry covariance matrix and is fit using restricted 
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maximum likelihood. Where a significant interaction was observed post-hoc comparisons were 
undertaken. Correction for multiple comparisons was made using the Benjamini-Hochberg 
method (false discovery rate restricted to 5%). Non-longitudinal data were compared using an 
unpaired t-test or a Mann-Whitney test as appropriate. Categorical data were compared using 
the chi-squared test. Statistical significance was assumed if P < 0.05. 
Results
Baseline characteristics at injury (T0) are shown in Table 1 and in supplementary 
Table E1. All animals completed the study protocol and were euthanized at T24. 
Respiratory variables
The use of ECMO facilitated a lower tidal volume ventilation strategy (4 (4-4) mL/kg 
ABW). The median ECMO flow rate was 2.75 L/min (2.5-3.25 L/min), with a sweep gas flow 
of 3 L/min (2-3.5 L/min). During VV-ECMO, animals had a median PaO2 of 109 mmHg (94-
131 mmHg) and a PaCO2 of 32 mmHg (30-35 mmHg). There were no significant differences 
in these parameters between groups (supplementary Figure E2). Animals were adequately 
anticoagulated during ECMO, as measured by activated partial thromboplastin time (aPTT) 
ratios. The dose of heparin was not significantly different between groups (supplementary 
Figure E2).
Because VV-ECMO controls gas exchange, native lung function was assessed one hour 
after cessation of extracorporeal flow and after the performance of a standardized lung 
recruitment manoeuvre (T24). As shown in Figure 2 both the PaO2/FiO2 ratio (p = 0.076) and 
the oxygenation index (OI) (p = 0.153) were numerically better in the carrier vehicle only 
group, the differences were not statistically significant. 
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The plateau airway and driving pressures were similar between groups at T24 (Figure 
2). Static lung compliance was also similar, both during and after ECMO (Figure 2). The use 
of a protocolized recruitment manoeuvre did not improve compliance after cessation of 
extracorporeal support in either group (Figure 2). 
Hemodynamic variables
This model of acute lung injury was associated with the development of hyperdynamic 
shock, which worsened over time (Figure 3). The administration of hMSCs resulted in 
significantly lower cumulative vasopressor doses (Figure 3). At T4, mean arterial pressure 
(MAP) was significantly higher in the hMSC treated group (p = 0.001), even though these 
animals received lower doses of noradrenaline (Figure 3). By T14, MAP was again similar 
between groups, although vasopressor requirements continued to be lower in hMSC treated 
animals. In addition, there were lower arterial lactate concentrations, higher arterial base 
excesses, and lower mean pulmonary artery pressures from 12 hrs (T14) post instillation in the 
hMSC group (Figure 3), however these were not statistically significant. Cumulative fluid 
balance at T24 was similar in both groups (Vehicle control, 2713 ± 970 mL vs. hMSCs, 2992 ± 
1237 mL, p = 0.648). 
Histopathology and lung injury 
The blinded assessment of lung tissue was conducted by an independent expert 
veterinary pathologist. Sections of the right lower lobe were prepared, and a lung injury score 
(LIS) was calculated (19). The administration of hMSCs resulted in significantly lower scores 
(p = 0.04) (Figure 4), principally mediated by a reduction in neutrophil infiltration. 
There were no significant differences in lung wet/dry ratio or bronchoalveolar lavage 
(BAL) total protein concentration (Figure 4). BAL fluid inflammatory cell counts are detailed 
in supplementary Table E4. There were no significant differences in these counts over time. 
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Similarly, there was no difference in lung tissue homogenate gene expression (as assessed by 
qPCR) between groups (supplementary Figure E3). 
In a post-hoc analysis, pulmonary arterial thrombosis was noted in 5 hMSC treated 
animals, but only one animal receiving carrier vehicle alone (p = 0.031).
Inflammatory cytokines
BAL and plasma cytokine concentrations were assessed longitudinally 
(supplementary Figure E4 and supplementary Figure E5). In BAL, statistically significant 
differences in IL-8 were observed at T3, T14, and T23 (p = 0.013, 0.016, and 0.028 respectively). 
In plasma, cytokine trajectories were similar between groups (supplementary Figure E5).
Hematological and biochemical measurements
A summary of hematological and biochemical values are provided in supplementary 
Tables E2 and E3. This lung injury model was associated with the development of acute 
kidney injury and abnormal liver function, although there were no significant differences in 
indices between groups. The administration of hMSCs resulted in a significantly lower 
lymphocyte count at T24 (p = 0.047) (supplementary Figure E5).
Cell-ECMO membrane interaction and cell fate
The administration of hMSCs was associated with a significant increase in the trans-
oxygenator pressure gradient, becoming apparent 4 hours after cell delivery (Figure 5). By T23, 
the mean pressure gradient in the hMSC group reached 64 ± 37 mmHg vs. 17 ± 9 mmHg in the 
vehicle only group. The instillation of carrier vehicle alone was associated with a reduction in 
the ECMO pump speed to flow ratio over time, a finding not observed in the hMSC group 
(Figure 5). During the study, there were no instances of pump or oxygenator failure requiring 
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a component exchange. Likewise, there was no evidence of clotting on the oxygenator surface 
by visual examination in either group.  
Membrane oxygenators from animals treated with hMSCs were isolated and preserved 
at the termination of ECMO, subsequent deconstruction and staining of the fiber bundles (n=7) 
revealed adherent cells exhibiting surface markers consistent with those of hMSCs 
(supplementary Figure E6). Similar cell populations were not apparent in vehicle only 
controls (n=3). 
Discussion
We carried out a trial of clinical-grade iPSC-derived hMSCs, given endobronchially, 
for acute lung injury in sheep during VV-ECMO. The main findings of this study can be 
summarized as follows; (1) with regard to the primary outcome, hMSCs did not improve 
oxygenation at 24 hours. (2) hMSCs did not improve pulmonary mechanics but did improve 
the severity of histological lung injury and reduced the concentration of bronchoalveolar lavage 
IL-8. (3) in spite of endobronchial administration, hMSCs adhered to and impacted the function 
of a commercial membrane oxygenator in-vivo - with an increase in the trans-membrane 
oxygenator pressure gradient. In addition, more pulmonary arterial thromboses were noted in 
hMSC-treated lungs. (4) hMSCs reduced the depth and severity of shock. 
This study was conducted in a large animal model of ARDS and ECMO, which 
replicates several important clinical features (20). The ‘double-hit’ injury applied in this study 
resulted in acute severe hypoxemic respiratory failure consistent with modern criteria for the 
use of VV-ECMO (11). To support the severe acute respiratory failure, we employed a 
commercial ECMO device which is in widespread clinical use. Additionally, our protocolized 
intensive care was consistent with clinical best practice standards (21). A common criticism of 
pre-clinical trials of MSCs has been the use of heterogeneous, non-clinical grade cell products 
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(1), however, we tested a commercial hMSC product which is under investigation in clinical 
trials. 
MSCs have been administered to patients with respiratory failure on ECMO (22, 23). 
These reports, which include only three patients, did not describe infusion-related adverse 
events although failed to fully characterize the interaction between MSCs and the 
extracorporeal device. Kocyildrim et al. have conducted the only other pre-clinical study 
involving both MSCs and ECMO for respiratory failure (24). Their ovine based, 6-hour pilot 
study did not report on the impact of MSC administration on the performance of ECMO.   
hMSCs and pulmonary function
In this study, the administration of hMSCs failed to improve oxygenation at T24. 
Furthermore, animals receiving hMSCs had a trend for worse oxygenation index values. In a 
phase 2a study of 60 patients with ARDS, the intravenous administration of hMSCs did not 
significantly improve PaO2/FiO2 ratio, although there was a signal toward improvement in 
oxygenation index in a post-hoc analysis (10). Pre-clinical studies of MSCs in ARDS have 
reported improvements in oxygenation, although few have produced lung injury as severe (25). 
In a recent systematic review of pre-clinical models combining ARDS and ECMO, only four 
achieved PaO2/FiO2 values <100 mmHg (20). The degree of lung injury in this model may 
explain why oxygenation is impaired in the treated group, despite improvements in 
inflammation and lung injury. Emerging research has highlighted the pro-coagulant effects of 
transplanted MSCs. These appear to be primarily mediated by MSC expression of tissue factor 
(26), but also by the secretion of pro-coagulant microvesicles (27) and by direct enhancement 
of platelet deposition (28). In pre-clinical experiments MSCs have been associated with the 
development of pulmonary emboli in-vivo (29). In this study, despite the use of heparin, almost 
all hMSC animals (n=6) had histological evidence of pulmonary arterial thrombosis at post-
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mortem. The presence of exogenous hMSCs within the disordered pulmonary vasculature may 
have contributed to impairments in oxygenation, tempered by the fact that there was no increase 
in mean pulmonary artery pressure in treated animals.            
Animals receiving hMSCs had improved composite histologic lung injury scores at 
post-mortem. The components of the score most influenced by hMSCs were neutrophil 
numbers in the alveolar and interstitial space. Multiple studies of MSCs in pre-clinical models 
of ARDS have demonstrated their ability to reduce neutrophil infiltration (30) and neutrophil 
extracellular trap formation (31). In this study, BAL neutrophil counts did not differ between 
groups. This may reflect the technical challenges of obtaining and assessing BAL cell counts. 
In a recent porcine model of ARDS and MSC therapy, a reduction in neutrophil infiltration was 
correlated with a reduction in BAL IL-8 concentrations (32), a finding confirmed in this study.  
hMSCs and the systemic inflammatory response
Multiple pre-clinical models (33) and recent clinical trials (34-37) have examined the 
use of MSCs in the treatment of septic shock. Animals receiving hMSCs required less 
vasopressor support throughout the experiment to achieve an equivalent or higher MAP. A 
similar, early but non-sustained, reduction in vasopressor requirement has previously been 
described in a large-animal model of septic shock treated with MCSs (38). hMSCs did not alter 
plasma concentrations of pro-inflammatory cytokines over extended time periods in this study, 
a finding which has previously been identified in other pre-clinical (39) and clinical studies 
(34). A recent Phase I dose escalation study of MSCs in patients with septic shock 
demonstrated that the maximum effect of cell therapy on plasma cytokine levels occurred at 4 
hours post-administration and declined with time (36). In this study, that time period coincides 
with the maximum separation in vasopressor dose, MAP, and levels of IL-1β and IL-6 between 
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groups. This may indicate that repeat dosing of MSCs will be required for optimal therapeutic 
efficacy.   
hMSCs and ECMO
The risk posed by MSCs to membrane oxygenators has been postulated for some time 
(1), but has only recently been shown to have an experimental basis. Our group has previously 
reported the ability of hMSCs to tightly adhere to the membrane fibers of a commercial 
oxygenator. This may have been the result of the known plastic avidity of MSCs (13). Recently, 
Cho et al. reported the loss of systemically administered MSCs in an ex-vivo model of veno-
arterial ECMO (15). 
Given the emerging signal that systemically administered MSCs may interact with 
membrane oxygenators, we decided to test endobronchial instillation in this study. Cardenes et 
al. have used 18F-fluorodeoxyglucose labelling to track the fate of both systemically and 
endobronchially administered MSCs in an ovine model of ARDS (40). While systemically 
administered cells have a wide biodistribution in the first 5 hours, endobronchially 
administered cells were retained at the site of instillation. There are key differences in our 
approach, including the means of inducing lung injury and its severity. 
Limitations
This study has some limitations. First, while our model of injury replicates several 
relevant features including severe respiratory and hemodynamic failure, clinical ARDS is 
usually caused by infection and develops over several days, often in patients with other 
comorbidities (41). Second, MSCs are known to exhibit different functional responses 
dependent on the contemporary milieu, which in some circumstances may be detrimental (42). 
This study may have modelled only one phase of acute lung injury and so hMSCs may have 
exerted an effect which may differ in other phases.  Third, while our model extended 21 hours 
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post cell or vehicle delivery, this may have been too short a period to observe some beneficial 
effects of the intervention. For example, it may be that the favourable effect of hMSCs on 
histological injury may have translated to improvements in oxygenation over a longer time 
period. Conversely, an extension of the study period in the face of rising trans-oxygenator 
pressure gradients in the hMSC group may have ultimately led to circuit failures. Fourth, the 
use of a lung recruitment maneuver and the assessment of native lung function off ECMO may 
have had several adverse effects and we cannot be certain that these effects did not differ 
between groups. This approach was taken due to the challenge of assessing native lung function 
during ECMO, particularly where a lower tidal volume ventilatory strategy has been adopted. 
The study protocol was designed prior to the publication of the ART randomized controlled 
trial (43). Fifth, the addition of an uninjured control group may have provided further insights 
into the distribution of hMSCs during VV-ECMO. Finally, the dose and method of delivery of 
hMSCs remain a matter of conjecture. Based on the findings of our previous work (14), we 
chose not to investigate intravenous administration. Likewise, based on clinical trial 
experience, we opted to administer a single, fixed-dose of hMSCs. It is possible that varying 
the dose and/or route of administration of hMSCs may alter their efficacy and safety profile 
during ECMO.  
Conclusion
In a 24-hour, ovine model of ARDS and VV-ECMO, we found that hMSC therapy was 
associated with impairment of the membrane oxygenator. The use of cell therapy did not result 
in improvements in oxygenation, the primary outcome of this study, but was associated with a 
reduction in histological evidence of lung injury and inflammation in the lung. Given these 
data we cannot currently recommend the administration of hMSCs during ECMO.    
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Figure Legends
Figure 1. Study schematic.
a Adjusted to maintain pH 7.30-7.45. Permissive hypercapnia was tolerated to a minimum pH of 7.15.
b PaO2 55 – 80 mmHg. If despite an FiO2 of 1.0 oxygenation targets were not met, PEEP was 
increased, maintaining plateau pressure ≤ 32 cmH2O. 
c Total PEEP (extrinsic PEEP + intrinsic PEEP) did not exceed 20 cmH2O. PEEP was permitted to be 
reduced to 5 cmH2O to maintain plateau pressure ≤ 30 cmH2O. If despite a PEEP of 5 cmH2O, plateau 
pressure > 30 cmH2O, tidal volume was reduced in 1 mL/kg steps until set at 4 mL/kg.
Figure 2. Oxygenation and respiratory parameters. 
a. PaO2/FiO2 ratio. b. Oxygenation index. c.  Airway pressures and lung compliance. Data are 
presented as mean (± 95% confidence interval). Where error bars intersect the x axis the 95% 
CI includes zero.
Figure 3. Hemodynamic variables.
a. Mean arterial pressure and vasopressor dose (mean). b. Mean pulmonary artery pressure. c. 
Cumulative vasopressor dose. d. Cardiac index, base deficit, and arterial lactate. Data are 
presented as mean (± 95% confidence interval). Where error bars intersect the x axis the 95% 
CI includes zero. ** - p < 0.01.
Figure 4. Histopathology and lung injury.
a. Representative images of lung parenchyma. All animals showed evidence of diffuse alveolar 
damage however the frequency and degree of injury differed between groups. Panel 1: 
extensive alveolar edema with interstitial leukocyte infiltration. Panel 2: marked leukocyte 
infiltration within alveolar spaces and larger airways.  Panel 3: some loss of alveolar structure 
with edema however a reduction in interstitial and alveolar leukocytes. Panel 4: preservation 
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of alveolar architecture with few leukocytes in the alveolar spaces. Panel 5 & 6: representative 
images of pulmonary arterial and arteriolar emboli (black arrows) in animals receiving hMCSs.  
b. Composite lung injury score (LIS), lung wet/dry ratio (right lower lobe). c. BAL total protein 
concentration. Data are presented as mean (± 95% confidence interval). * - p = < 0.05.
Figure 5. Cell-ECMO interaction. 
a. Trans-membrane oxygenator pressure gradient. b. Pump revolutions per minute (RPM)/flow 
ratio. Data are presented as mean (± 95% confidence interval). Where error bars intersect the 
x axis the 95% CI includes zero. * - p = < 0.05.
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Table 1. Baseline physiological characteristics
Overall (n=14) Vehicle (n=7) hMSCs (n=7)
Weight (kg) 52.6 ± 3 52.4 ± 3.2 52.9 ± 2.6
Pre-ECMO tidal volume (mL/kg) 6.0 ± 0.1 6.0 ± 0.1 6.0 ± 0.1
At time of injury (T0)
Peak airway pressure (cmH2O) 31.5 ± 4.2 31.9 ± 3.3 31.1 ± 4.9
Plateau pressure (cmH2O) 26.5 ± 3.9 26.1 ± 3.9 26.9 ± 3.8
Driving pressure (cmH2O) 16.5 ± 3.9 16.1 ± 3.9 16.9 ± 3.8
Static compliance (mL/cmH2O) 21 ± 5.0 19 ± 4.6 23 ± 4.6
PaO2/FiO2 59 ± 20 58 ± 23 61 ± 17
PaCO2 (mmHg) 41 (38-46) 38 (38-41) 44 (41-48)
pH 7.36 ± 0.05 7.38 ± 0.04 7.34 ± 0.05
Bicarbonate (mmol/L) 23.2 ± 1.5 23.6 ± 1.4 22.9 ± 1.5
Base deficit (mmol/L) 1.30 ± 1.31 0.94 ± 1.15 1.66 ± 1.37
Arterial lactate (mmol/L) 1.6 ± 0.7 1.8 ± 0.6 1.4 ± 0.7
Heart rate (bpm) 102 (96-117) 108 (98-128) 98 (95-103)
Mean arterial pressure (mmHg) 103 ± 19 96 ± 16 111 ± 19
Central venous pressure (mmHg) 13 (11-13) 12 (11-13) 13 (13-14)
Mean pulmonary artery pressure 
(mmHg) 25 (16-29) 20 (17-27) 28 (19-29)
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A. Sheep preparation
Female sheep (Ovis aries, Border Leicester Cross), aged 1-3 years, were selected at random 
from a flock of healthy farm reared animals. Sheep were transferred to the animal research 
facility at least two weeks before use. They could graze freely in an outdoor enclosure and 
underwent veterinary inspection, including testing for common ovine pathogens (e.g. Q fever). 
On the day before experimentation, animals were housed in an indoor pen with free access to 
water and were denied solid feed for 12 hours. On the morning of experimentation, sheep were 
transported to the operating theatre in a specially modified sling. 
Under local anesthesia (5-10 mL 2% lignocaine, Pfizer, Sydney, NSW, Australia), a quad-
lumen central venous catheter (Arrow, Teleflex Medical Australia, Mascot, NSW, Australia) 
was inserted into the left external jugular vein (EJV), after which baseline blood samples were 
obtained. An 8 Fr percutaneous introducer sheath (Arrow, Teleflex Medical Australia, Mascot, 
NSW, Australia) was inserted cephalad to the central venous catheter in the left EJV. Two 8 Fr 
percutaneous introducer sheaths were then inserted, approximately 8 cm apart, in the right EJV. 
All lines were secured with 1-0 silk sutures. Once vascular access was secured, animals were 
pre-oxygenated for 3 minutes using a facemask and a Mapleson C anesthetic circuit set to 
deliver 15 L O2 min-1. General anesthesia was then induced as described below. Animals were 
transferred to an operating table and positioned supine. A surgical tracheostomy was 
performed, by midline longitudinal incision exposing the space between the 2nd/3rd tracheal 
rings. A size 9.0 Portex tracheostomy tube (Smith’s Medical Australia, Sydney, NSW, 
Australia) was inserted, and positioning was confirmed using a flexible video bronchoscope 
(aScope™, Ambu, Ballerup, Denmark). Thereafter, the tracheostomy was suctioned hourly 
using an in-line suction catheter.    
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B. Supportive care protocol
Experienced medical and nursing staff, with training in the prevision of critical care and 
ECMO, were present for the duration of each experiment. Expert large animal veterinarian 
advice was available upon request. 
Anesthesia/analgesia
General anesthesia was induced by intravenous injection of midazolam (0.5 mg/Kg, 
Pfizer, Sydney, NSW, Australia) and ketamine (5 mg/kg, Troy Laboratories, Sydney, NSW, 
Australia). Animals were orotracheally intubated (size 9.0-10.0 ID Portex endotracheal tube, 
Smith’s Medical Australia, Sydney, NSW, Australia) and connected to a mechanical ventilator. 
Maintenance of anesthesia/analgesia was achieved by intravenous infusion of midazolam (0.5-
0.8 mg/kg/hr, Pfizer, Sydney, NSW, Australia), ketamine (5-7.5 mg/kg/hr, Troy Laboratories, 
Sydney, NSW, Australia), and fentanyl (5-10 mcg/kg/hr, Hameln Pharmaceuticals, Hameln, 
Germany). Depth of anesthesia was assessed prior to neuromuscular blockade by abolition of 
the eyelash reflex, after which attention was paid to clinical indicators such as heart rate and 
salivation. Total intravenous anesthesia was maintained until euthanasia.
Once maintenance anesthesia was established, animals were paralysed with an 
intravenous bolus of vecuronium (50 mcg/kg, Pfizer, Sydney, NSW, Australia). Adequacy of 
neuromuscular blockade (NMB) was assessed using the train of four (TOF) response to 
peripheral nerve stimulation. NMB was maintained through the course of the experiment by an 
intravenous infusion of vecuronium (50 mcg/kg/hr, Pfizer, Sydney, NSW, Australia). 
Mechanical ventilation
In the period between induction of anesthesia and the commencement of VV-ECMO, 
animals were ventilated according to a protocolized lung-protective strategy (Table A). In a 
volume-controlled mode, the ventilator was initially set to achieve a tidal volume (Vt) of 6 
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mL/kg actual body weight (ABW). One of, a Hamilton Galileo (Hamilton Medical, Bonaduz, 
Switzerland) or a Puritan Bennett 840 (Puritan Bennett, Medtronic, Dublin, Ireland) ventilator 
was used for the full course of each study. 
Parameter Value
Mode Volume controlled
Tidal Volume (Vt) 4 - 6 mL/kg 
Respiratory Rate ≤ 35 breaths per minutea
FiO2 Lowest required for SpO2 88-93%b
PEEP Adjusted to maintain Pplat 28-30 cmH2Oc
Plateau Pressure (Pplat) ≤ 30 cmH2O
I:E Ratio 1:1 to 1:3
Table A. Pre-ECMO ventilatory strategy.
a Adjusted to maintain pH 7.30-7.45. Permissive hypercapnia was tolerated to a minimum pH of 7.15.
b PaO2 55 – 80 mmHg. If despite an FiO2 of 1.0 oxygenation targets were not met, PEEP was 
increased, maintaining Pplat ≤ 32 cmH2O. 
c Total PEEP (extrinsic PEEP + intrinsic PEEP) did not exceed 20 cmH2O. PEEP was permitted to be 
reduced to 5 cmH2O to maintain Pplat ≤ 30 cmH2O. If despite a PEEP of 5 cmH2O, Pplat > 30 cmH2O, 
Vt was reduced in 1 mL/kg steps until set at 4 mL/kg.
FiO2 – Fraction of inspired oxygen, SpO2 – Peripheral oxygen saturation, PEEP – Positive end-
expiratory pressure, Pplat – Airway plateau pressure, I:E Ratio – Inspiratory to expiratory ratio
Fluid and electrolyte management 
After the induction of general anesthesia, a maintenance infusion of crystalloid (1-2 
mL/kg/hr, compound sodium lactate, Baxter, Sydney, NSW, Australia) was commenced for 
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the duration of the study. Fluid therapy was indicated at other times to support hemodynamics 
or ECMO flows, in this case 100 mL boluses of compound sodium lactate were titrated to 
effect. 
Electrolyte levels were assessed 4-hourly. Serum potassium levels were maintained > 
3.5 mmol/L by i.v. infusion of 10-20 mmol potassium chloride (AstraZeneca, Sydney, NSW, 
Australia). In the event of hyperkalemia (K+ > 5.5 mmol/L), supplemental potassium 
administration was ceased and 10 mL 10% calcium gluconate (B. Braun Melsungen AG, 
Melsungen, Germany) was given by i.v. bolus injection. Hyperchloremia (Cl- >103) was 
avoided. All large volume gastric losses were returned via the orogastric tube. Blood glucose 
levels were measured hourly and maintained > 1.5 mmol/L by infusion of 50% glucose (Baxter, 
Sydney, NSW, Australia).
Monitoring and hemodynamic management
All animals were monitored according to the ‘Recommendations for standards of 
monitoring during anaesthesia and recovery 2015: Association of Anaesthetists of Great 
Britain and Ireland’, including; pulse oximetry, 3-lead electrocardiogram, and continuous 
waveform capnography. In addition, the central venous catheter (CVC) was transduced as a 
measure of central venous pressure.
Following induction of general anesthesia and repositioning to the operating table, 
invasive arterial blood pressure monitoring was established by cannulation of the left facial 
artery (20G Leadercath arterial, Vygon, Écouen, France). Using the 8 Fr percutaneous sheath 
introducer positioned in the left EJV, a pulmonary artery catheter (PAC) was inserted (7.5 Fr 
Swan-Ganz CCOmbo, Edwards Life Sciences, Irvine, CA, USA). The catheter was inserted to 
a depth of 15 cm after which the flotation balloon was inflated. The catheter was directed to 
the pulmonary artery, the balloon was deflated, and the catheter secured. Positioning was 
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confirmed by obtaining a satisfactory waveform. Continuous cardiac output monitoring 
(Vigilance monitor, Edwards Lifesciences, Irvine, CA, USA) was instituted, with cardiac index 
estimated by; cardiac output/BSA [weight (kg)0.67 x 0.0842]. Continuous measurements of core 
body temperature were also obtained from the PAC. 
A 14 Fr urinary catheter (Gildana Healthcare, Oakleigh, VIC, Australia) was inserted 
and connected to an hourly urometer to allow for accurate quantification of urine output. A 16 
Fr orogastric tube (ConvaTec, Glen Waverley, VIC, Australia) was inserted and left on free 
drainage. 
A mean arterial pressure ≥ 65 mmHg was targeted. In the face of sustained hypotension, 
repeated 100 mL boluses of compound sodium lactate (Baxter, Sydney, NSW, Australia) were 
given until; CVP ≥ 8 mmHg and/or the animal was no longer fluid responsive (failure to 
increase stroke volume > 10% by PAC). Thereafter, noradrenaline (80 mcg/mL in 5% dextrose, 
Hospira, Lake Forrest, IL, USA) was commenced at 80 mcg/min and the dose titrated at 5-
minute intervals. If noradrenaline requirements reached 2400 mcg/min, vasopressin (PPC, 
Richmond Hill, Canada) was commenced at 0.8 units/hr and increased to a maximum of 1.8 
units/hr. 
Euthanasia
At the end of each study, animals were euthanised by i.v. injection of phenobarbitone 
(142.5 mg/kg, Aspen Pharma, Dandenong, NSW, Australia). After death was confirmed 
(absence of cardiac electrical activity, blood pressure, and cardiac output monitoring), organs 
were retrieved surgically. Animal carcasses were stored and subsequently disposed of by 
incineration.
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C. Model of experimental ARDS
After instrumentation, in a supine position, animals were injured using a combination of 
intravenous oleic acid (OA) and endobronchial E. coli lipopolysaccharide (LPS).
Oleic acid preparation
A total dose of 0.06 ml/kg OA was used to induce injury. Firstly, 0.03 mL/kg OA 
(O1008, Sigma-Aldrich, Castle Hill, NSW, Australia) was suspended in 20 mL arterial blood 
and 150 IU porcine heparin (Pfizer, Sydney, NSW, Australia). This mixture was administered 
via the distal port of the right EJV central venous catheter, followed by a flush of 50 mL 0.9% 
sodium chloride (Baxter, Sydney, NSW, Australia). The animal could recover and after 15 
minutes this procedure was repeated. When 15 minutes elapsed from the second dose, arterial 
blood gas analysis, at an FiO2 of 1.0 and a PEEP of 10 cmH2O, was used to confirm a PaO2/FiO2 
ratio <100 mmHg.
E. coli lipopolysaccharide preparation
Immediately after a PaO2/FiO2 ratio <100 mmHg was confirmed, 50 mcg E. coli LPS 
(O55:B5, Sigma-Aldrich, Castle Hill, NSW, Australia), diluted in 10 mL 0.9% sodium chloride 
(Baxter, Sydney, NSW, Australia), was administered, via a designated video bronchoscope, to 
each main bronchus.  
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D. Veno-venous ECMO
Equipment
ECMO was performed using a Maquet ROTAFLOW centrifugal pump (Maquet, 
Getinge Group, Rastatt, Germany) along with a Maquet Permanent Life Support (PLS) set 
(Maquet, Getinge Group, Rastatt, Germany). Circuits were primed in a sterile fashion (prime 
volume ~ 585 mL) with compound sodium lactate (Baxter, Sydney, NSW, Australia). 
Cannulation
Cannulation attempts were commenced after injury was confirmed (T0). Two 19 Fr 
Bio-medicus single-stage venous catheters (Medtronic, Dublin, Ireland) were used in a right 
sided VEJ – VEJ configuration. The access cannula was inserted by first re-wiring the proximal 
right EJV percutaneous sheath and was then positioned in the inferior vena cava at the level of 
the diaphragm. The return cannula was inserted by first re-wiring the distal right EJV 
percutaneous sheath and was then positioned with the tip at the cavo-atrial junction. Cannula 
insertion and positioning were guided by fluoroscopy and real-time intra-cardiac and intra-
cannular echocardiography. Cannulae were flushed with heparinised 0.9% sodium chloride (10 
IU/mL porcine heparin, Pfizer, NSW, Australia). Cannulae were secured by suturing to the 
skin. Animals were then placed in sternal recumbency for the remaining duration of the study. 
Management
Once cannulation was successfully completed and positioning was confirmed, VV-
ECMO was commenced (T1).  Pump speeds were slowly increased to 1000 rpm before clamp 
release. Pump speeds were then adjusted to achieve flow rates of ~2/3 CO (typically between 
60-90 mL/kg). Fresh gas flow (FGF) was initially set at 80% of pump flow and adjusted based 
on arterial blood gas analysis. The FGF blender was set to deliver 100% O2 at all times. During 
ECMO, PaO2 will be maintained ≥ 65 mmHg and PaCO2 ≤ 45 mmHg. Hyperoxia (PaO2 > 150 
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mmHg) will be avoided.  A water heater-cooler unit was connected to the membrane 
oxygenator and set to 38° C for the duration of the ECMO run. 
At the beginning of VV-ECMO, animals received a bolus dose of unfractionated 
heparin (20 IU/kg porcine heparin, Pfizer, Sydney, NSW, Australia), when the activated 
clotting time (ACT) fell below 160 s an infusion was commenced at 4 IU/kg/hr. An ACT of 
180 s-210 s was targeted. ACT was measured prior to ECMO, at 1 hour, 2 hours, and every 2 
hours thereafter. The unfractionated heparin infusion was titrated as per a pre-defined protocol 
(Table B). 
ACT Response
< 130 Bolus 10 IU/kg and increase infusion by 1.5 IU/kg/hr
130 - 150 Increase infusion by 1 IU/kg/hr 
150 - 180 Increase infusion by 0.5 IU/kg/hr
180 - 210 No change
210 – 250 Decrease infusion by 1 IU/kg/hr
> 250 Cease infusion for 1 hr and recheck ACT, restart when ACT < 210 AND decrease infusion by 1.5 IU/kg/hr
Table B. ECMO anti-coagulation titration protocol.
Mechanical ventilation during ECMO
Once VV-ECMO was established, mechanical ventilation was adjusted to target an 
ultra-protective ventilatory strategy, consistent with that described in the EOLIA trial (1). 
Neuromuscular blockade was maintained throughout. Ventilator settings and targets are 
detailed further in Table C.
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Termination and return to pre-ECMO mechanical ventilation 
VV-ECMO was halted 23 hours after injury (T23). Pump speeds were gradually 
reduced to zero and both cannulae were clamped. Pump blood was returned by unclamping the 
return cannula and gently flushing the circuit with Compound Sodium Lactate (~585 mL blood 
returned). Clamped cannulae were left in situ until termination of the study. Immediately before 
cessation of VV-ECMO, a standardised recruitment manoeuvre was performed. The 
recruitment manoeuvre involved a 40 s breath hold at an airway pressure of 40 cmH20, in a 
pressure-controlled mode, with an FiO2 of 1.0. After which animals were returned to 
standardised pre-ECMO ventilator settings (with an FiO2 of 1.0) for 60 minutes at which time 
the trial was terminated.
Parameter Value
Mode Volume controlled
Tidal Volume ≤ 4 ml/kg 
Respiratory Rate 8 breaths per minute
FiO2 0.30
PEEP ≥ 10 cmH2O
Pplat ≤ 25 cmH2O
I:E Ratio 1:1 to 1:3
Table C. ECMO ventilatory strategy.
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E. Human mesenchymal stromal cells
Induced pluripotent stem cell (iPSC) derived human mesenchymal stromal cells 
(hMSCs) were obtained from Cynata Therapeutics Ltd. (CYP-001; Cynata Therapeutics Ltd., 
Melbourne, VIC, Australia). Cells were manufactured under Good Manufacturing Practices 
(GMP) conditions and were > 99% positive for CD-73, CD-90, and CD-105, but negative for 
CD-31 and CD-45. iPSC-derived hMSCs were between passage 3 and 5. iPSC derived hMSCs 
were presented in discrete batches of 1 x 108 cells, suspended in 20 mL of a carrier vehicle 
(57.5% Plasmalyte-A, 40% Flexbumin 25%, 2.5% Dimethyl sulfoxide). Cells were shipped to 
our laboratory stored in the vapour phase of liquid nitrogen at -80°C where this was maintained 
until use. 
Cell preparation
Two hours before administration, cryopreserved cells in their carrier vehicle were thawed in a 
water bath at 37.5°C, agitated to prevent clumping, and decanted into a sterile container. 
Batches were sampled and assessed for viability (> 95%) prior to use.  
Cell administration
Animals allocated to the treatment group received a fixed endobronchial dose of 3 x 
108 cells (suspended in 60 mL of carrier vehicle), via a flexible video bronchoscope (aScope™, 
Ambu, Ballerup, Denmark). Those allocated to the control group, received an equal volume of 
cell-free carrier vehicle, administered in an identical fashion. Common to both groups, 25 mL 
of solution was administered to the left diaphragmatic lobar bronchus and 5 mL to the left 
apico-cardiac lobar bronchus, with a further 25 mL administered via the right diaphragmatic 
lobar bronchus and 5 mL via the right cardiac lobar bronchus. The right apical lobar bronchus, 
which arises in sheep directly from the trachea at approximately the level of the third rib (2), 
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was untreated. After each instance of cell delivery, the channel of the bronchoscope was 
flushed with 5 mL of 0.9% sodium chloride (Baxter, Sydney, NSW, Australia).    
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F. Clinical measurements
Hemodynamic and ventilatory data (including data derived from the PAC) were 
continuously monitored and automatically recorded at 5-minute intervals using a data 
monitoring system (Solar 8000, GE Healthcare, Waukesha, WI, USA) coupled with custom 
software.  Pressure readings across the membrane oxygenator were made using a silicone-based 
pressure transducer (Omega Engineering, Norwalk, CT, USA), these data were recorded 
continuously using LabVIEW software (National Instruments, Austin, TX, USA). ECMO flow 
readings and pump revolutions were read and recorded on an hourly basis from the 
ROTAFLOW console (Maquet, Getinge Group, Rastatt, Germany). Urine and oro-gastric 
outputs were recorded on a pre-piloted observation chart on an hourly basis, while continuous 
temperature data were taken from the PAC.  
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G. Blood and bronchoalveolar lavage fluid analyses
Blood
Whole blood was sampled from the facial artery catheter. Arterial blood gas analysis 
was undertaken on at least an hourly basis (ABL800 FLEX, Radiometer, Copenhagen, 
Denmark). At baseline, T-1, T0, T1-4, T6, T14, T23, and T24, blood was sampled for routine 
laboratory hematological and biochemical testing. These tests were undertaken in a blinded 
fashion by an accredited veterinary pathology laboratory (IDEXX Laboratories Pty. Ltd., 
Brisbane, QLD, Australia). At baseline, T-1, T0, T1-4, T6, T14, T23, and T24, blood was sampled 
for plasma cytokine measurements. The concentration of IL-6, IL-1β, IL-8 and IL-10 in plasma 
and bronchoalveolar lavage (BAL) fluid was quantified by in-house ELISAs using methods 
published previously (3-5). Positive internal controls were used to ensure that inter- and intra- 
plate variability was < 10% and confirm the precision and accuracy of all ELISA assays.
Bronchoalveolar lavage fluid
BAL was undertaken by an experienced bronchoscopist using a video bronchoscope 
(aScope™, Ambu, Ballerup, Denmark). At each examination the right and left middle and 
lower lobes were sampled. Each lobe was injected with 20 mL sterile 0.9% sodium chloride 
(Baxter, Sydney, NSW, Australia) and gentle suction was applied. The lavage fluid was 
collected in a sterile universal container. BAL fluid was centrifuged, and the supernatant 
collected for ELISA analysis. Aliquots were also cytospun onto slides for inflammatory cell 
counts. 
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H. Histological analyses and lung tissue gene expression
After the confirmation of death, the heart and lungs were retrieved enbloc via a midline 
sternotomy. Lung tissue was set on ice and portions of left and right lower and upper lobe lung 
tissue were fixed in 10% buffered formalin for at least 24 hours, processed and embedded in 
paraffin. All sections (5 µm) were stained with haematoxylin and eosin. Sections were 
examined by an independent, blinded, veterinary pathologist and scored for features of lung 
injury (6). 
Total RNA was isolated from lung tissue using the Invitrogen PureLink® RNA Mini Kit 
(Thermo Fisher Scientific, VIC, Australia). All samples were DNase treated (Invitrogen DNA-
free™ DNA Removal kit; Thermo Fisher Scientific) and the concentration of RNA determined 
using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, DE, USA). First 
strand cDNA was synthesized from 1μg of RNA (iScript™ Select cDNA Synthesis kit; Bio-
Rad, NSW, Australia). 
A non-exhaustive panel of genes associated with epithelial, endothelial, and coagulative 
function were analysed. These genes have been associated with dysfunction in ARDS. In 
addition, a panel of matrix metalloproteinase genes and their regulators were analysed. Real-
time Quantitative PCR was performed using primers for MMP1, MMP2, MMP7, TIMP1, 
TIMP2, AGER, VEGFA, ANGPT2, F3, vWF and SFTPD (PrimerDesign, Southampton, UK) 
with PrecisionFAST qPCR SYBR Green Master Mix with low ROX (Primer Design). 
Reactions consisted of 10 μL SYBR Green Master Mix, 1 μL mixed primers (300 nM), and 5 
μL of cDNA (equivalent to 50 ng) and nuclease free water to a final volume of 20 μL. The 
cycling conditions were as follows: cDNA was denatured at 95°C for 2 min, followed by 40 
cycles of 95°C for 5 s and 60°C for 20 s. Melt curve analysis was programmed at the end of 
the run, 60–90°C with increments rising by 0.5°C each step and a 5 s hold at each degree to 
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determine reaction specificity and the absence of contamination, mispriming and primer dimer. 
A no-template control was included for each primer set. An ovine specific SYBR Green 
reference gene assay (Primer Design) was used to evaluate the stability of six candidate 
normalization genes (GAPDH, RPL19, β-2M, ACTB, RPS26, YWHAZ) using real-time 
quantitative PCR. The Qbase PLUS program was used to identify the most stably expressed 
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Gene 
Symbol































Table D. Primers used in qPCR analysis.
a PCR efficiencies were determined using the formula 10-1/slope
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I. Analyses of membrane oxygenators
At the cessation of VV-ECMO (T23) the circuit was disassembled and the membrane 
oxygenator (MO) was recovered. The MO was rinsed with 0.9% sodium chloride (Baxter, 
Sydney, NSW, Australia) until the effluent was observed to be clear, after which the MO was 
infused with 500 mL formaldehyde and then sealed. MOs were stored at 5° C overnight and 
then opened using a commercially available band saw. The fiber bundle was extracted, and 
approximate 5 cm x 5 cm sections were taken from the heat and gas exchange sections. These 
were stored in sterile containers in Phosphate Buffered Saline (PBS) until they were analyzed. 
For immunohistochemical detection of MSCs, approximately 1 cm x 1 cm fiber sections 
were blocked for 3 hours in 2% HISS (heat inactivated sheep serum) and 0.5% triton X-100 in 
PBS. The samples were washed 3 times in PBS for 5 minutes each, followed by overnight 
incubation with primary antibodies at 4°C. After primary incubation, the fiber sections were 
washed 3 times in PBS for 5 minutes each, incubated in secondary antibody solution for 1 hour 
at room temperature, and then washed an additional 3 times in PBS for 5 minutes each. Primary 
antibodies: mouse Ab to CD105-FITC (ab18278, 1:10), rabbit Ab to CD73 (ab175396, 1:50), 
goat Ab to CD90 (ab189367, 1:100). Secondary antibodies: donkey anti-mouse 488 
(Invitrogen, 1:100), donkey anti-rabbit 647 (Invitrogen, 1:100), donkey anti-goat 568 
(Invitrogen, 1:100). Nuclei were counterstained with 1 µg/mL DAPI (4′,6-diamidino-2-
phenylindole, Sigma-Aldrich, NSW, Australia) during secondary incubation. All antibodies 
were diluted in blocking solution during primary and secondary incubations. A widefield Nikon 
deconvolution microscope was used to acquire images using both 4X and 20X objectives. Final 
images were processed with ImageJ software.
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J. Sample size calculation
Prior to the study commencing, a sample size calculation was undertaken based on a primary 
outcome of improvement in PaO2/FiO2 ratio. Using data from two previous trials of MSCs in 
ovine models of ARDS (7, 8), we calculated that 7 animals per group were required to detect a 
100 mmHg difference in PaO2/FiO2 ratio (alpha 0.05, power 0.9, outcome SD 42 mmHg, paired 
test).
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At time of injury (T0)
Haemoglobin (g/L) 106.7 ± 8.3 112.6 ± 7.1 100.9 ± 4.3
Haematocrit 0.322 ± 0.030 0.339 ± 0.032 0.306 ± 0.010
White cell count (x10^9/L) 1.8 (1.0-2.3) 1.6 (1.0-2.1) 2.0 (1.1-3.0)
Neutrophil count (x10^9/L) 0.4 (0.2-0.9) 0.3 (0.2-0.4) 0.9 (0.2-1.4)
Lymphocyte count (x10^9/L) 1.1 (0.9-1.4) 1.1 (0.8-1.3) 1.0 (0.9-1.5)
Monocyte count (x10^9/L) 0.1 (0-0.2) 0.2 (0.1-0.3) 0.1 (0-0.1)
Prothrombin time (s) 15.3 ± 1.6 16.3 ± 1.3 14.5 ± 1.3
Activated partial thromboplastin 
time (s)
24.6 ± 2.5 24.0 ± 3.0 25.2 ± 2.0
Sodium (mmol/L) 139 ± 3 140 ± 2 137 ± 3
Potassium (mmol/L) 3.6 (3.3-3.9) 3.6 (3.3-4.0) 3.5 (3.4-3.8)
Chloride (mmol/L) 106 (105-106) 106 (105-107) 105 (103-106)
Urea (mmol/L) 5.7 ± 1.1 5.9 ± 1.0 5.5 ± 1.3
Creatinine (mmol/L) 0.07 (0.06-0.07) 0.07 (0.06-0.07) 0.06 (0.06-0.07)
Albumin (g/L) 26 ± 2 26 ± 2 27 ± 2
Bilirubin (µmol/L) 3 (1-4) 3 (3-5) 1 (1-3)
Alkaline phosphatase (IU/L) 102 ± 26 89 ± 22 114 ± 23
Aspartate aminotransferase (IU/L) 83 (72-97) 82 (72-95) 84 (73-103)
Creatinine kinase (IU/L) 205 (205-242) 242 (200-299) 191 (162-255)
Supplementary Table E1. Baseline hematological and biochemical characteristics.
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Haemoglobin (g/L) 78.9 ± 14.1 78.6 ± 18.0 79.3 ± 7.1 0.930
Haematocrit 0.249 ± 0.040 0.247 ± 0.050 0.252 ± 0.023 0.855
White cell count (x10^9/L) 1.1 (0.8-1.4) 1.1 (0.9-2.2) 1.2 (0.7-1.3) 0.606
Neutrophil count (x10^9/L) 0.2 (0.2-0.5) 0.2 (0.2-0.9) 0.4 (0.1-0.5) 0.494
Lymphocyte count (x10^9/L) 0.7 ± 0.3 0.8 ± 0.4 0.6 ± 0.2 0.243
Monocyte count (x10^9/L) 0.1 (0.1-0.3) 0.1 (0.1-0.3) 0.2 (0.1-0.2) 0.779
Prothrombin time (s) 28.3 ± 5.7 27.8 ± 5.3 29.1 ± 6.3 0.755
Activated partial thromboplastin 
time (s)
45.5 ± 7.0 44.3 ± 7.9 47.8 ± 4.3 0.482
Sodium (mmol/L) 140 (137-141) 141 (138-142) 140 (136-141) 0.331
Potassium (mmol/L) 4.4 ± 0.7 4.4 ± 0.6 4.3 ± 0.7 0.857
Chloride (mmol/L) 111 (109-112) 112 (110-113) 111 (109-112) 0.331
Urea (mmol/L) 4.5 ± 1.2 4.7 ± 1.5 4.2 ± 0.8 0.493
Creatinine (mmol/L) 0.11 ± 0.03 0.11 ± 0.02 0.11 ± 0.03 0.654
Albumin (g/L) 16 ± 2 16 ± 2 15 ± 2 0.355
Bilirubin (µmol/L) 18 ± 5 19 ± 6 17 ± 4 0.436
Alkaline phosphatase (IU/L) 54 ± 15 56 ± 20 53 ± 8 0.735
Aspartate aminotransferase (IU/L) 171 (144-207) 200 (155-247) 143 (138-196) 0.259
Creatinine kinase (IU/L) 7498 ± 4079 8990 ± 4233 6006 ± 3303 0.482
Supplementary Table E2. Hematological and biochemical characteristics at the end of 
ECMO (T23).
*  P values corrected for multiple comparison.
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Supplementary Table E3. Hematological and biochemical characteristics at T24.








Haemoglobin (g/L) 87.5 ± 13.6 86.0 ± 12.8 89.0 ± 14.2 0.733
Haematocrit 0.268 ± 0.040 0.265 ± 0.039 0.270 ± 0.041 0.846
White cell count (x10^9/L) 1.2 (1.0-1.6) 1.6 (1.1-2.0) 1.2 (0.9-1.3) 0.266
Neutrophil count (x10^9/L) 0.4 (0.1-0.6) 0.4 (0.2-0.8) 0.4 (0.1-0.6) 0.381
Lymphocyte count (x10^9/L) 0.7 (0.7-1.0) 1.0 (0.8-1.1) 0.7 (0.6-0.7) 0.047
Monocyte count (x10^9/L) 0.1 (0.1-0.1) 0.2 (0-0.3) 0.1 (0.1-0.1) 0.433
Prothrombin time (s) 29.5 ± 5.0 31.5 ± 5.9 27.9 ± 3.3 0.346
Activated partial thromboplastin 
time (s)
47.3 ± 4.5 47.7 ± 3.3 47.0 ± 5.2 0.831
Sodium (mmol/L) 139 (138-141) 140 (138-142) 139 (135-140) 0.139
Potassium (mmol/L) 4.4 ± 0.5 4.5 ± 0.5 4.4 ± 0.6 0.886
Chloride (mmol/L) 111 ± 4 112 ± 5 110 ± 2 0.392
Urea (mmol/L) 4.3 ± 1.0 4.4 ± 1.2 4.2 ± 0.8 0.839
Creatinine (mmol/L) 0.11 ± 0.03 0.11 ± 0.02 0.11 ± 0.03 0.656
Albumin (g/L) 17 ± 2 17 ± 2 17 ± 1 0.896
Bilirubin (µmol/L) 19 ± 8 19 ± 9 18 ± 7 0.960
Alkaline phosphatase (IU/L) 57 ± 18 53 ± 24 58 ± 10 0.992
Aspartate aminotransferase 
(IU/L) 190 (162-222) 185 (164-217) 191 (161-221) 0.931
Creatinine kinase (IU/L) 8008 ± 3351 8858 ± 2734 7157 ± 3679 0.415
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Supplementary Table E4. Bronchoalveolar lavage fluid cell counts. 
Pooled BAL from right and left lower lobes. Two hundred cells per count. * P values 






BAL Monocytes/macrophages (n/200 cells ± SD)
T-1 194 ± 4 193 ± 5 0.005
T0 189 ± 8 186 ± 10
T2 148 ± 37 163 ± 13
T3 100 ± 54 118 ± 36
T4 38 ± 28 74 ± 52
T6 33 ± 26 37 ± 28
T14 37 ± 38 14 ± 13
T23 21 ± 10 11 ± 12
BAL Neutrophils (n/200 cells ± SD)
T-1 4 ± 4 6 ± 5 0.008
T0 9 ± 6 12 ± 9 
T2 51 ± 37 36 ± 9
T3 96 ± 54 80 ± 34
T4 156 ± 29 123 ± 51
T6 162 ± 26 158 ± 28
T14 160 ± 37 184 ± 13
T23 178 ± 11 186 ± 13
BAL Lymphocytes (n/200 cells ± SD)
T-1 2 ± 2 1 ± 1 0.169
T0 2 ± 6 2 ± 3
T2 1 ± 1 1 ± 1
T3 2 ± 3 0 ± 1
T4 2 ± 2 1 ± 1
T6 2 ± 3 0 ± 1
T14 1 ± 1 1 ± 1
T23 0 ± 1 2 ± 2
BAL Eosinophils (n/200 cells ± SD)
T-1 0 ± 0 0 ± 0 0.295
T0 0 ± 1 0 ± 1
T2  1 ± 1 1 ± 2
T3 2 ± 3 2 ± 2
T4 4 ± 4 2 ± 2
T6 3 ± 4 1 ± 2
T14 3 ± 3 1 ± 1
T23 2 ± 2 1 ± 1
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Figure E1. Bronchoscopic hMSC delivery
Volumes of carrier fluid instilled and location of delivery within the ovine pulmonary tree.
Figure E2.  ECMO management
a. ECMO system variables and gas exchange on ECMO. Points represent individual 
observations. Dashed lines represent lower (PaO2) and upper (PaCO2) targets. b. 
Anticoagulation during ECMO. Activated partial thromboplastin time (APTT) ratio and 
heparin dose are presented as mean (± 95% confidence interval).
Figure E3. Lung tissue qPCR
a. Matrix metalloproteinases (MMPs) and inhibitors (TIMPS). b. Tissue factor (F3). c. 
Epithelial markers. AGER – receptor for advanced glycation endpoints, SPFTD – surfactant 
protein D. d. Endothelial markers. ANGPT2 – angiopoietin-2, VEGFA – vascular endothelial 
growth factor A, vWF – von Willebrand factor. Results are presented as mean (± 95% 
confidence interval). 
Figure E4. Bronchoalveolar lavage fluid cytokines
Data presented as mean (± 95% confidence interval). Where error bars intersect the x axis the 
95% CI includes zero.  * - p <0.05.
Figure E5. Plasma cytokines and leukocytes
a. Plasma cytokine concentrations. b. Leukocyte counts in whole blood. Data presented as 
mean (± 95% confidence interval). Where error bars intersect the x axis the 95% CI includes 
zero. . * - p <0.05.
Figure E6. Immunofluorescence of explanted oxygenator fibers. 
DAPI - 4′,6-diamidino-2-phenylindole.
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